ImmuCell Corporation

NasdaqCM:ICCC Stock Report

Market Cap: US$45.9m

ImmuCell Dividends and Buybacks

Dividend criteria checks 0/6

ImmuCell does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-8.4%

Buyback Yield

Total Shareholder Yield-8.4%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Dec 04
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Nov 30
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

Aug 07
Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Aug 10
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

May 27
Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

ImmuCell GAAP EPS of -$0.09, revenue of $3.86M

Aug 11

ImmuCell announces preliminary 2Q sales of $3.9M

Jul 07

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Sep 15
Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

Jun 10
Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Mar 15
Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

Jan 22
Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

ImmuCell reports FY20 preliminary sales

Jan 07

ImmuCell restructures its bank debt

Dec 15

ImmuCell EPS beats by $0.04, beats on revenue

Nov 12

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ICCC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICCC's dividend payments have been increasing.


Dividend Yield vs Market

ImmuCell Dividend Yield vs Market
How does ICCC dividend yield compare to the market?
SegmentDividend Yield
Company (ICCC)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (ICCC) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ICCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ICCC's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ICCC has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 13:06
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation